# The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

> **NCT03739203** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 752 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Cariprazine
- **DRUG:** Placebo
- **DRUG:** Antidepressant Therapy (ADT)

## Key facts

- **NCT ID:** NCT03739203
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-10
- **Primary completion:** 2021-09-06
- **Final completion:** 2021-09-06
- **Target enrollment:** 752 (ACTUAL)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739203, "The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03739203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*